Lilly allocates $1.42 billion for Zyprexa settlement

10/21/2008 | Wall Street Journal, The

Eli Lilly and Co. said it expects to pay $1.42 billion to settle litigation with the U.S. Attorney's Office in Philadelphia involving claims that the company downplayed the adverse effects of Zyprexa when it promoted the psychiatric drug for off-label use. Lilly said it is in advanced talks with prosecutors and is willing to "intensify efforts to resolve these issues."

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA